FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months.
暂无分享,去创建一个
M. Baccarani | P. Piccaluga | M. Rondoni | S. Paolini | G. Martinelli | D. Cilloni | F. Messa | G. Saglio | T. Grafone | E. Ottaviani | F. Pane | F. Buccisano | M. Tiribelli | M. Malagola | S. Merante | M. Palmisano